Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    21376385 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Conditions: Metastatic Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention: Drug: Bevacizumab and eribulin
2 Completed
Has Results
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: E7389;   Drug: Physician's Choice

Indicates status has not been verified in more than two years